Sugi Predict

Sugi Predict / Compounds / SCHEMBL2867465

SCHEMBL2867465

SCHEMBL2867465

COc1ccc(C)c(-n2nc3c(c2N)c(=O)[nH]c2cc(O)c(OC)cc23)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.37
▸ EPHB4 P54760 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ GAA P10253 3/20 0.35
▸ TYMS P04818 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ ADORA3 P0DMS8 3/20 0.34
▸ ADORA1 P30542 2/20 0.34
▸ DHFR P00374 1/20 0.34
▸ PDE2A O00408 1/20 0.34
▸ MAPT P10636 4/20 0.33
▸ PKM P14618 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870423 0.92 KDM4E (0.38) EPHB4KDM4EALDH1A1GAATYMS
SCHEMBL2862251 0.90 PDE2A (0.42) EGFRKDM4ETYMSADORA3ADORA1
SCHEMBL2861115 0.89 ADORA3 (0.40) EGFRKDM4EALDH1A1GAATP53
SCHEMBL2863002 0.87 KDM4E (0.39) EPHB4KDM4EALDH1A1GAATYMS
SCHEMBL2860224 0.85 RET (0.39) EGFRKDM4EALDH1A1GAATP53
SCHEMBL2872669 0.83 ESR2 (0.39) EPHB4KDM4EALDH1A1GAATYMS
SCHEMBL2868559 0.83 ADORA3 (0.47) EPHB4KDM4EALDH1A1HPGDHTT
SCHEMBL2856187 0.82 ABCG2 (0.38) EPHB4KDM4EALDH1A1GAATYMS
SCHEMBL2861593 0.81 CTSL (0.43) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2864664 0.80 TDP2 (0.43) EGFRKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 — — US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 EGFR 1575/4885EPHB4 1769/4885KDM4E 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.